Expert opinion on existing and developing drugs to treat female sexual dysfunction

References

• :history of the manual: American Psychiatric Association; 2015 [ cited 2018 May 15]. Available from: (https://www.emsisd.com/cms/lib/TX21000533/Centricity/Domain/1580/DSM_%20History%20of%20the%20Manual%20_%20psychiatry.pdf)
   Google Scholar
• American Psychiatric Association . DSM-5 Task Force., PsychiatryOnline Premium Package, et al. Diagnostic and statistical manual of mental 585 disorders DSM-5. Washington, D.C.: American Psychiatric Association; 2013. Available doi: from: (https://doi.org/10.1176/appi.books.9780890425596)
   Google Scholar
• Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions-part II. J Sex Med. 2016 Dec;13(12):1888–1906. PubMed PMID: 27843072.
   PubMedGoogle Scholar
• Clayton AH, DeRogatis LR, Rosen RC, et al. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal. J Sex Med. 2012 Aug;9(8):2040–2046. PubMed PMID: 23586432.
   PubMed Web of Science ®Google Scholar
• Clayton A, Goldstein I, Kim NN, et al. The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clinic Proc. 2018 Apr;93(4):467–487.
   PubMed Web of Science ®Google Scholar
• Aggarwal RS, Mishra VV, Panchal NA, et al. Sexual dysfunction in women: an overview of risk factors and prevalence in Indian women. Jaypee. 2012;4(3):134–136.
   Google Scholar
• Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach. Am Fam Physician. 2015 Aug 15;92(4):281–288. PubMed PMID: 26280233.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008 Nov;112(5):970–978. PubMed PMID: 18978095.
   PubMed Web of Science ®Google Scholar
• Lodise NM. Female sexual dysfunction: a focus on flibanserin. Int J Womens Health. 2017;9:757–767. PubMed PMID: 29066935; PubMed Central PMCID: PMCPMC5644557.
   PubMed Web of Science ®Google Scholar
• Sharma JB, Kalra B. Female sexual dysfunction: assessment. J Pak Med Assoc. 2016 May;66(5):623–626. PubMed PMID: 27183952.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: international Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017 Jan;92(1):114–128. PubMed PMID: 27916394.
   PubMed Web of Science ®Google Scholar
• Krause M, Wheeler TL 2nd, Snyder TE, et al. Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg. 2009 May;15(3):105–114. PubMed PMID: 22229022; PubMed Central PMCID: PMCPMC3252029.
   PubMedGoogle Scholar
• Lindahl SH. Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health. 2014;6:307–312. PubMed PMID: 24648775; PubMed Central PMCID: PMCPMC3958523.
   PubMedGoogle Scholar
• Simon J, Nachtigall L, Ulrich LG, et al. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010 Oct;116(4):876–883. PubMed PMID: 20859151.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015 Apr;18(2):233–240. PubMed PMID: 25335119; PubMed Central PMCID: PMCPMC4438339.
   PubMed Web of Science ®Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt). 2018 Jan;27(1):14–23. PubMed PMID: 29064335; PubMed Central PMCID: PMCPMC5771532.
   PubMed Web of Science ®Google Scholar
• Prasterone (Intrarosa) for dyspareunia. Med Lett Drugs Ther. 2017 Sep 11;59(1529):149–150. PubMed PMID: 28880846.
   PubMed Web of Science ®Google Scholar
• Pharmaprojects database, copyright to Citeline: Informa Business Intelligence; [cited 2018 Mar 2]. Available from: https://pipeline.citeline.com/cpHome.aspx
   Google Scholar
• Berman JR, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology. 1999 Sep;54(3):385–391. PubMed PMID: 10475340.
   PubMed Web of Science ®Google Scholar
• Bancroft J, Graham CA, Janssen E, et al. The dual control model: current status and future directions. J Sex Res. 2009 Mar-Jun;46(2–3):121–142. PubMed PMID: 19308839.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Giraldi A, Pfaus J. Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med. 2013 Jan;10(1):36–49. PubMed PMID: 22974089.
   PubMed Web of Science ®Google Scholar
• Georgiadis JR, Kringelbach ML, Pfaus JG. Sex for fun: a synthesis of human and animal neurobiology. Nat Rev Urol. 2012 Sep;9(9):486–498. PubMed PMID: 22926422.
   PubMed Web of Science ®Google Scholar
• Pfaus JG. Revisiting the concept of sexual motivation. Annu Rev Sex Res. 1999;10:120–156. PubMed PMID: 10895250.
   PubMedGoogle Scholar
• Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010 Jul;71(7):821–822. PubMed PMID: 20667289.
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Burrows GD, Wood C, et al. Hormones and sexuality: effect of estrogen and progestogen. Obstet Gynecol. 1980 Sep;56(3):316–322. PubMed PMID: 7422170.
   PubMed Web of Science ®Google Scholar
• Krebs CJ, Jarvis ED, Pfaff DW. The 70-kDa heat shock cognate protein (Hsc73) gene is enhanced by ovarian hormones in the ventromedial hypothalamus. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1686–1691. PubMed PMID: 9990085; PubMed Central PMCID: PMCPMC15561.
   PubMed Web of Science ®Google Scholar
• Reis SL, Abdo CH. Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors. Clinics (Sao Paulo). 2014;69(4):294–303. PubMed PMID: 24714838; PubMed Central PMCID: PMCPMC3971358.
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002 Apr p[2./kjjki;77 Suppl 4:S42–S48. PubMed PMID: 12007901.
   PubMed Web of Science ®Google Scholar
• Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res. 2005 Sep–Oct;17(5):399–408.
   PubMed Web of Science ®Google Scholar
• Moynihan R. FDA panel rejects testosterone patch for women on safety grounds. Br Med J. 2004 Dec;329(7479):1363. .
   PubMed Web of Science ®Google Scholar
• Traish A, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;pii:S2050-0521(18)30046–5.
   Google Scholar
• Both S. Recent developments in psychopharmaceutical approaches to treating female sexual interest and arousal disorder. Curr Sex Health Rep. 2017;9(4):192–199. PubMed PMID: 29225554; PubMed Central PMCID: PMCPMC5711968.
   PubMedGoogle Scholar
• Tuiten A, van Rooij K, Bloemers J, et al. Efficacy and safety of on-demand use of 2 treatments designed for different etiologies of female sexual interest/arousal disorder: 3 randomized clinical trials. J Sex Med. 2018 Feb;15(2):201–216.
   PubMed Web of Science ®Google Scholar
• Shadiack AM, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137–1144. PubMed PMID: 17584134.
   PubMed Web of Science ®Google Scholar
• Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy. 2013 Apr;33(4):411–421. PubMed PMID: 23553810.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016 Jun;12(3):325–337. PubMed PMID: 27181790; PubMed Central PMCID: PMCPMC5384512.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Jordan R, Kingsberg S, et al., editors. Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): efficacy analyses from the reconnect study. Pipeline presentation. American Society of Clinical Psychopharmacology Annual Meeting; 2017 June 1; Miami, FL.
   Google Scholar
• Pyke RE, Katz M, Segraves RT, et al. Phase IIa study of a proprietary combination of bupropion and trazodone for hypoactive sexual desire disorder (HSDD) in premenopausal women: novel responder and remitter results. Poster presentation at the Annual Meeting of the American Society of Clinical Psychopharmacology; 2015 June 22–25; Miami, FL.
   Google Scholar
• Lo Monte G, Graziano A, Piva I, et al. Women taking the “blue pill” (sildenafil citrate): such a big deal? Drug Des Devel Ther. 2014;8:2251–2254. PubMed PMID: 25422584; PubMed Central PMCID: PMCPMC4232035.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Buisson O, Rubio-Casillas A. Beyond the G-spot: clitourethrovaginal complex anatomy in female orgasm. Nat Rev Urol. 2014;11(9):531–538.
   PubMed Web of Science ®Google Scholar
• Gao L, Yang L, Qian S, et al. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet. 2016 May;133(2):139–145. PubMed PMID: 26797204.
   PubMed Web of Science ®Google Scholar
• Kielbasa LA, Daniel KL. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother. 2006 Jul-Aug;40(7–8):1369–1376. PubMed PMID: 16757679.
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Pluchino N, Bernardi F, et al. Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women. Neuropsychiatr Dis Treat. 2006 Sep;2(3):299–307. PubMed PMID: 19412477; PubMed Central PMCID: PMCPMC2671819.
   PubMedGoogle Scholar
• Garefalakis M, Hickey M. Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. Clin Interv Aging. 2008;3(1):1–8. PubMed PMID: 18488873; PubMed Central PMCID: PMCPMC2544356.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018 Sep;25(9):1033–1045. .
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010 Mar;17(2):281–289. .
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010 Apr;13(2):132–140. .
   PubMed Web of Science ®Google Scholar
• Allahdadi KJ, Tostes RC, Webb RC. Female sexual dysfunction: therapeutic options and experimental challenges. Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):260–269. PubMed PMID: 19538161; PubMed Central PMCID: PMCPMC3008577.
   PubMedGoogle Scholar
• Pacher P, Mabley JG, Liaudet L, et al. Topical administration of a novel nitric oxide donor linear polyethylenine-nitric oxide/nucleophile adduct (DS1), selectively increases vaginal blood flow in anesthetized rats. Int J Impot Res. 2003;15:461–464.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Nappi RE. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. 2018 Jul;6(3):384–395. Epub 2018 Jan 19.
   PubMed Web of Science ®Google Scholar